Jui-Fu Hsiao's Contact Details

Jui-Fu Hsiao's Company Details

SyneuRx International (Taiwan) Corp.

, New Taipei City, Taiwan • 8 Employees
Research

MissionThe mission of SyneuRx is to use a humanistic approach to bring breakthrough therapeutics to diseases and conditions where there are significant unmet needs.Antiviral Platform - Antiviral for COVID-19Currently, SyneuRx is conducting two clinical programs of COVID-19 treatments— Pentarlandir® as an oral capsule and Airnecflu® as an inhaled treatment. The company's COVID-19 efforts began in February 2020 as COVID-19 emerged to be a global pandemic, SyneuRx decided to apply its extensive R&D experience with CNS therapeutics toward R&D for COVID-19 antivirals in an effort to help develop a safe, effective, and accessible treatment that would prevent the progression and transmission of the disease.SyneuRx scientists arrived at the theory that regulatory enzymes such as protease would be a critically-important ‘drug target' for these types of illnesses, which coincidentally is also a target for several virally-caused diseases such as HIV and hepatitis. Researchers decided to test the company's proprietary library of compounds against the protease and discovered that the compound that became Pentarlandir proved to be the most safe and efficacious in preclinical tests.Pentarlandir's ability to block coronavirus replication was confirmed in multiple, rigorous cellular studies and it was also proved to maintain an excellent safety profile, which made Pentarlandir an ideal candidate to go into clinical development. NMDA Platform - Modulation For CNS DisordersA New Perspective on Brain Function ModulationSyneuRx believes that NMDA receptors are the grand regulator of the brain. Therefore, solutions to the current unmet needs in many central nervous system (CNS) disorders need to involve therapies that modulate NMDA receptor functions.